Open AccessPatients with Ankylosing Spondylitis Can Maintain Clinical and Functional Improvement after Switching from Infliximab Reference Product to Infliximab Biosimilar (REMSIMA): 12 Months Comparative Open-Label Study
Author(s) -
Abdulsatar J. Mathkhor,
Ali Altaqi,
Abdulnasser Abdullah,
Amer Khudhairy
Publication year - 2022
Publication title -
journal of clinical rheumatology and immunology
Language(s) - English
Resource type - Journals
eISSN - 2661-3425
pISSN - 2661-3417
DOI - 10.1142/s266134172250002x
Subject(s) - infliximab , basdai , medicine , ankylosing spondylitis , basfi , biosimilar , erythrocyte sedimentation rate , spondylitis , surgery , gastroenterology , rheumatoid arthritis , disease , psoriatic arthritis